R. Mcnally

发表

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

K. Nackaerts, M. Socinski, F. Shepherd, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors

W. Read, Sunil Sharma, A. Mita, 2013, Cancer Chemotherapy and Pharmacology.

A case of acute myelofibrosis with complex karyotypic changes: a type of myelodysplastic syndrome.

R. Branda, E. F. Allen, R. Mcnally, 1996, Cancer genetics and cytogenetics.

Coordination of Care for Breast Reconstruction Patients: A Provider Survey

C. Anders, A. Deal, Clara N. Lee, 2017, Clinical breast cancer.

Patterns and temporal trends in the incidence of childhood and adolescence cancer in Cyprus 1998-2017: A population-based study from the Cyprus Paediatric Oncology Registry.

A. Borkhardt, L. Sharp, Friederike Erdmann, 2022, Cancer epidemiology.

Nipple-Sparing Mastectomy in the Community Setting

Donald S. Mowlds, J. Harness, A. Salibian, 2017 .

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

M. Galsky, M. Renschler, R. Jotte, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

G. Curigliano, K. Saini, E. de Azambuja, 2020, European Journal of Cancer.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

D. Ettinger, R. Salgia, P. Lorigan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.

D. Ettinger, P. Lorigan, D. Spigel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy.

M. Renschler, R. Jotte, P. Conkling, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

K. Saini, E. de Azambuja, M. Saini, 2020, Oncology and Therapy.

Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)

K. Nackaerts, M. Socinski, F. Shepherd, 2012 .

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

V. Miller, R. Erlich, Siraj M. Ali, 2014, Case Reports in Oncology.

Baseline CD3+CD56+ (NKT-like) Cells and the Outcome of Influenza Vaccination in Children Undergoing Chemotherapy

I. Jankovics, T. Berki, G. Ottóffy, 2021, Frontiers in Immunology.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

D. Ettinger, R. Salgia, P. Lorigan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.